Clear Impact logo

Vermont Medicaid/CHIP (CCS-21)

AMR: Asthma Medication Ratio: Age 5–18 (CCS-21)

Current Value

70.4%

2021

Definition

Line Bar

Notes on Methodology

  • This measure was new to the Child Core Set in 2018. It replaces the Medication Management for People with Asthma measure , which was included in the 2013-2017 Child Core Sets.
  • The annual reported rate captures activity during the previous calendar year. 
  • This is a Healthcare Effectiveness & Data Information Set (HEDIS) administrative measure.
  • DVHA’s rates only include Medicaid Primary beneficiaries in HEDIS administrative measures.
  • There is no HEDIS benchmark available for this age range.

Story Behind the Curve

This measure looks at the percentage of members ages 5 to 18 who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

Medications for asthma are usually categorized into long-term controller medications used to achieve and maintain control of persistent asthma and quick-reliever medications used to treat acute symptoms and exacerbations. Appropriate ratios for these medications could potentially prevent a significant proportion of asthma-related costs (hospitalizations, emergency room visits, missed work and school days).

Last updated:  August 2021

Clear Impact Suite is an easy-to-use, web-based software platform that helps your staff collaborate with external stakeholders and community partners by utilizing the combination of data collection, performance reporting, and program planning.

Scorecard Container Measure Action Actual Value Target Value Tag S A m/d/yy m/d/yyyy